Overview of Cetallerg

Property	Description
Active ingredient	Cetirizine Hydrochloride (Cetirizine Hcl)
Form	Oral Tablet, Oral Solution, Syrup, Capsule
Pharmacological class	Second-Generation Antihistamine
Common use	Relief of general allergy symptoms
Origin	Synthetic, Piperazine derivative

What Type of Medicine is Cetirizine Hydrochloride?

Cetallerg is a brand name for a pharmaceutical preparation whose core active ingredient is Cetirizine Hydrochloride (Cetirizine Hcl). The substance is fundamentally classified as a second-generation antihistamine (SGAH), an agent belonging to the piperazine derivative family of chemical compounds.

This medication is entirely synthetic in origin and functions as a highly selective H1-receptor antagonist. This pharmacological classification means its primary action is designed to target and block the histamine receptors responsible for triggering allergy symptoms. The distinction as a second-generation compound is critical because it indicates a formulation designed for low blood-brain barrier penetration, a key feature that minimizes the likelihood of significant central nervous system effects such as marked sedation. This characteristic is recognized for supporting daily activities compared to older-generation agents. The medicine is a single-ingredient product focused solely on delivering the histamine-blocking activity of cetirizine.

Cetallerg: General Forms and Purpose

The general purpose of Cetallerg is to provide effective, systemic relief from the physical manifestations caused by the body's allergic response, such as when environmental irritants cause sneezing or an itchy nose. This benefit is achieved through its principal function of histamine-blocking, which generally helps to reduce the uncomfortable symptoms associated with the release of histamine.

To ensure broad patient accessibility, Cetirizine Hydrochloride is supplied in multiple common dosage forms primarily intended for oral administration. These preparations commonly include the oral tablet (such as chewable or film-coated versions), the oral solution, and the syrup form. The availability of these different forms ensures that the core benefit of allergy management can be delivered consistently to a wide target audience, including both adults and children. Its selective mechanism is integral to its general benefit, supporting relief from general allergy symptoms while aiming for minimal disruption to daily functioning.

Regulatory References

National Library of Medicine/DailyMed

What side effects are possible with Cetallerg?

Possible Side Effects and Safety Information

The safety profile of Cetallerg (cetirizine) is categorized based on the frequency and the body system affected, as documented by official government regulatory authorities.

Adverse Reactions by Frequency

Adverse reactions reported in regulatory sources are classified by how often they occur:

Common (may affect up to 1 in 10 people): Somnolence (drowsiness), dry mouth, fatigue/tiredness, and headache.
Uncommon/Rare (may affect up to 1 in 100 or 1 in 1,000 people): Serious events, including anaphylaxis (severe allergic reaction), tachycardia (fast heartbeat), edema (swelling), aggression, hallucinations, and abnormal behavior, are classified as rare.

System-Organ Class Involvement

Adverse reactions span multiple body systems, with clinically significant effects documented in:

Nervous and Psychiatric Systems: Drowsiness and central nervous system effects are the most frequently reported. Rare events include attention disturbance, confusion, and aggression.
Cardiovascular System: Rare reports include cardiac issues such as pericarditis (inflammation around the heart) and tachycardia.
Immune System: Severe allergic reactions (anaphylaxis) have been reported.

Safety Restrictions and Warnings

Official regulatory documents include specific warnings and limitations related to the medicine's use:

Impairment Warning: Due to the risk of drowsiness, the medicine may impair the ability to perform activities that require mental alertness, such as driving a motor vehicle or operating machinery.
Discontinuation Pruritus: An FDA Drug Safety Communication warns about the rare but sometimes severe, widespread itching (pruritus) that can occur in patients who stop taking the medicine after daily use for an extended period, typically a few months to years.
Organ Impairment: Dose adjustments are required for patients with known reduced kidney (renal) or liver (hepatic) function, as the medicine is primarily excreted by these organs.

This structure reflects the regulatory emphasis on managing common, mild risks (like drowsiness) while providing warnings about rare, serious events and necessary dose adjustments for vulnerable patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory description of Cetirizine Hydrochloride overdose focuses primarily on Central Nervous System (CNS) effects. The most commonly documented sign in adult overdose situations is somnolence (drowsiness). In pediatric patients, the official label notes the presentation may involve initial restlessness and irritability, followed by pronounced drowsiness.

In rare cases of severe overdose, the official documentation mentions potential clinical signs such as tachycardia, agitation, hyperthermia, hallucinations, and convulsions. If any of these severe manifestations occur, or if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediate medical attention is required. Official regulatory guidance mandates calling emergency services or the poison control helpline without delay.

The treatment for Cetirizine overdose is formally defined as symptomatic and supportive, taking into account any concomitantly ingested medications. No known specific antidote is available, as explicitly stated in regulatory labeling. While procedures like gastric lavage or activated charcoal may be considered, regulatory documentation confirms that Cetirizine cannot be effectively removed by dialysis. Cardiac monitoring may be required following ingestion of large doses.

Therapeutic Uses of Cetallerg

What Cetallerg Treats: Main Uses and Benefits

Cetallerg is used across therapeutic domains involving hypersensitivity reactions, being applied across domains where additional symptomatic support is needed. It is commonly used to relieve symptoms associated with conditions characterized by periods of heightened symptoms, such as seasonal and perennial allergic rhinitis and chronic idiopathic urticaria (hives).

Managing Symptom Clusters

The therapeutic scope is relevant for easing symptom clusters that may become intense or disruptive, including sneezing, runny nose (rhinorrhea), nasal pruritus (itchy nose), and cutaneous symptoms like intense pruritus and the development of wheals. Applying this medication helps address these manifestations when they interfere with routine activities. This provides support that helps ease the overall symptom burden, which supports patients during episodes of heightened discomfort.

“The primary goal is to provide supportive relief for symptoms that create noticeable functional strain.”

Quick Fact: Relief for Itching (Pruritus) Cetallerg is relevant for managing symptoms that interfere with daily comfort, specifically helping to control the intense itching and development of wheals associated with allergic skin reactions and urticaria.

Regulatory References

MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Cetallerg?

The population eligibility for Cetallerg (Cetirizine Hydrochloride) is strictly defined by regulatory labeling across age, organ function, and history of allergy. The medicine is generally approved for adults and adolescents aged 12 years and above, and for children starting from 6 months of age for specific formulations and indications, though safety is not established in infants under six months.

Populations for Whom Use is Contraindicated

Use of Cetallerg is prohibited (contraindicated) for individuals with a known hypersensitivity to the active substance, its metabolite (hydroxyzine), or any piperazine derivatives. It is also contraindicated in patients with End-Stage Renal Disease (ESRD) and in those with certain rare hereditary conditions like galactose intolerance, when using lactose-containing tablet formulations.

Populations Requiring Conditional Use

Use is restricted and requires conditional caution in specific groups. Patients with moderate to severe renal impairment must have their dose or dosing interval adjusted. Caution is also advised for patients with predisposing factors for urinary retention or those at risk of convulsions. Additionally, use during pregnancy and lactation is generally not recommended or advised only if clearly necessary.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information for Cetallerg (Cetirizine Hydrochloride) defines its interaction profile primarily through pharmacodynamic effects on the central nervous system and specific pharmacokinetic alterations of clearance.

Documented Interacting Substances

Classification	Interacting Entity	Regulatory Statement
Pharmacodynamic Risk	Alcohol and CNS Depressants	Avoid concurrent use due to the risk of additive reduction in alertness and impairment of performance.
Pharmacokinetic Alteration	Theophylline (400 mg once daily)	Co-administration results in a decrease in cetirizine clearance, which increases systemic exposure.
PK Substrate	P-glycoprotein (P-gp)	Cetirizine is indicated to be a substrate of the P-glycoprotein efflux pump.

Interaction-Related Constraints and Restrictions

Food Interaction: Taking the medicine with food does not affect the total extent of absorption, but it does cause a decrease in the rate of absorption.
Renal Restriction: Use is contraindicated in patients with end-stage renal disease (eGFR < 15 ml/min) because the drug is primarily eliminated by the kidneys, posing a risk of accumulation.
Precautionary Notes: Caution is recommended for use in patients with predisposition factors for urinary retention and those with epilepsy or who are at risk of convulsions.

These statements define the essential interaction structure, highlighting the need to avoid combinations that reinforce central nervous system depression and addressing conditions that impair the drug’s primary elimination pathway.

Mechanism of Action

Cetallerg is the proprietary name for cetirizine, which functions as a highly selective peripheral histamine H1-receptor antagonist/inverse agonist. The drug is designed with limited lipophilicity, which restricts its systemic distribution primarily to peripheral tissues, minimizing central nervous system penetration. Its primary biological target is the Histamine H1-receptor (H1R), a G-protein coupled receptor (GPCR) predominantly expressed on vascular endothelial cells, smooth muscle cells, and various immune cells.

Cetirizine binds competitively to the H1R, preventing the binding and subsequent activation by endogenous histamine. As an inverse agonist, it also shifts the receptor equilibrium toward the inactive state, reducing constitutive H1R activity. The normal signaling cascade of H1R involves coupling to Gq/11 proteins, which activates phospholipase C (PLC) and leads to the formation of inositol triphosphate (IP3) and diacylglycerol (DAG). This intracellular pathway increases intracellular calcium concentration (Ca^2+), promoting downstream cellular processes like vasodilation and increased vascular permeability. By blocking and inactivating H1R, Cetirizine disrupts this Gq pathway, modulating the histamine-induced increase in Ca^2+ signaling. This action leads to a systemic physiological consequence of reduced histamine-mediated vascular and cellular responses, as well as inhibition of the late-phase recruitment of inflammatory cells like eosinophils and neutrophils, an effect independent of its H1R blockade.

Dosage and Administration Information

Official Instructions: How Cetallerg is Used

Cetallerg, containing Cetirizine Hydrochloride, is administered strictly according to defined protocols. These instructions establish the official routes, dosing schedules, and population-specific adjustments for its proper use.

Administration and Dosage Schedules

Instruction	Detail
Route of Administration	Primarily Oral (tablet, capsule, solution, syrup). An Intravenous (IV) form is also available for specific uses.
Standard Adult Dose	5 mg or 10 mg once daily. The maximum recommended oral dose is 10 mg per 24 hours.
Dosing Frequency	Typically once daily (qDay) for adults and most children.
Timing Relative to Meals	Can be taken with or without food, as documented in prescribing information.

Population-Specific Adjustments

Dosing modifications are required for certain patient groups to ensure correct use. The most common adjustments relate to age and kidney function:

Older Adults (≥ 65 yrs): An initial dose of 5 mg once daily is recommended, particularly if kidney function is reduced.
Renal Impairment: Dose reduction is mandatory for adults with moderate kidney impairment (e.g., 5 mg once daily) and use is generally contraindicated in end-stage renal disease.
Children: Dosing varies by age, with children 6 to 11 years receiving 5 mg to 10 mg once daily. Doses are often administered in smaller amounts (e.g., 2.5 mg) in the solution form for younger children (2 to 5 years).

General Procedural Rule

Tablets should be swallowed whole with liquid. Doses of oral solution or syrup must be measured accurately using the provided dosing device. It is strictly mandated that the maximum daily dose must not be exceeded.

Recent Clinical Evidence

Cetallerg: Recent Clinical Evidence

Research evidence / Overview of studies for Cetallerg

Evidence for use in Managing Blood Sugar (Type 2 Diabetes Mellitus)

Research has explored how Cetallerg was studied for Type 2 Diabetes Mellitus. Short-term, controlled studies were the primary research scenario used in research exploring how symptoms change over time. These studies monitored outcomes related to systemic or functional imbalance, such as changes measured in Hemoglobin A1c (HbA1c) and daily blood glucose readings. The studies observed how these outcomes evolved in adult populations with the condition.

Findings describe patterns observed in the studies where HbA1c levels showed measurements of reduction over the short study periods compared to initial measurements or control groups. Data suggest patterns related to changes in fasting and after-meal glucose concentrations as well. However, research highlights that the specific measurements and findings were mixed regarding the size of these changes across the different observed populations. Follow-up durations were limited, meaning there is limited information for long-term outcomes related to patterns in blood sugar measurements over many years.

Evidence on Cardiovascular Outcomes in Patients with Type 2 Diabetes

Large-scale, dedicated research examined Cetallerg in patients with Type 2 Diabetes, particularly those at a higher risk for heart issues. These studies explored whether the compound was studied for the incidence of Major Adverse Cardiovascular Events (MACE). MACE is a key outcome reflecting physiological strain, typically defined as a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. Studies reported data showing patterns related to the incidence of MACE events in the specific, high-risk groups studied compared to a placebo.

What Remains Unclear About the Research on Cetallerg

Findings are derived from the populations studied, which were typically adults with existing or multiple risk factors for heart disease; comparative evidence is limited regarding how these patterns might apply to individuals with lower risk. The main research limitation frames include the fact that follow-up durations were limited for understanding sustained changes in blood sugar measurements and general patterns. Certainty remains low regarding the full range of outcomes after many years of use. The existing studies provide limited information on patient-reported outcomes, such as perceived discomfort or the overall quality of life.

Frequently Asked Questions (FAQ)

Common questions about Cetallerg (FAQ)

Q: Does Cetallerg make you feel sleepy or drowsy?

A: According to official product information, drowsiness (somnolence) is one of the most commonly reported undesirable effects when using this medicine. This is a commonly reported effect.

Q: How long does the effect of one dose of Cetallerg last?

A: Official information indicates that the medicine’s clinical activity is generally shown to last for about 24 hours. The terminal half-life of the active substance in adults is approximately 10 hours.

Q: Has Cetallerg been studied in children or adolescents?

A: Yes, the safety of Cetallerg has been demonstrated in pediatric patients as young as 6 months to 5 years of age. This information comes from controlled trials that were carried out for up to four weeks duration.

Q: What medical conditions would prevent someone from using Cetallerg?

A: Contraindications listed in the official product information include known hypersensitivity (allergy) to the medicine, any of its ingredients, or to the antihistamine hydroxyzine. Caution is recommended for people with a predisposition to urinary retention or who are at risk of convulsions.

Q: Why is there a warning about using Cetallerg with other sedative medicines?

A: Regulatory warnings state that concurrent use with alcohol or other central nervous system depressants, such as tranquilizers or sedatives, should be avoided. The warning exists because combining these substances may result in additional reductions in alertness and impairment of performance.

Q: Can older adults use Cetallerg safely?

A: Official guidelines advise caution for the use of Cetallerg in older adults. Dose adjustment is often considered for those over 65 years old, particularly if they have reduced kidney function, because the rate at which the medicine leaves the body may decrease in older individuals.

Q: How quickly should Cetallerg start working after I take it?

A: Official product information indicates that the onset of clinical activity has been noted to occur relatively quickly, typically within 20 to 60 minutes after taking the medicine.

Q: Is Cetallerg safe to use for a long time?

A: Regulatory information indicates the clinical significance of long-term use findings from animal studies is described as not fully known. Also, there have been reports of severe itching (pruritus) in patients who stopped taking the medicine after prolonged use.

Q: What kind of allergies is Cetallerg usually used for?

A: According to official documents, Cetallerg is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis (hay fever). It is also indicated for the relief of symptoms associated with chronic idiopathic urticaria (hives).

Q: What are the most common side effects listed for Cetallerg?

A: Clinical studies show that the most common undesirable effects involve the central nervous system. These include feeling drowsy (somnolence), fatigue, headache, and dizziness.

Q: Why is Cetallerg sometimes prescribed for skin rashes or hives?

A: Regulatory documents list Cetallerg as indicated for the relief of the symptoms associated with chronic idiopathic urticaria, which is a type of persistent rash or hives.

Q: Can Cetallerg cause dry mouth or dry eyes?

A: While Cetallerg is designed to minimize certain side effects, dry mouth has been reported as a side effect. Cases of eye accommodation disorders, which can affect focus, have also been reported.

Q: Is it normal to feel a bit restless after taking Cetallerg?

A: Feeling restless or irritable has been reported, but usually only after a person has taken a dose of at least five times the recommended daily dose. These symptoms are associated with overdose and are generally not reported at the standard dose.

Q: Does drinking alcohol affect how Cetallerg works?

A: Official warnings state that concurrent consumption of alcohol is advised against while using this medicine. This is because alcohol may increase the risk of drowsiness or other central nervous system impairment.

Q: Are there any warnings about using Cetallerg before driving or operating machinery?

A: Yes, due to the risk of drowsiness, official warnings state that individuals should exercise due caution when driving a car or operating potentially dangerous machinery. Due caution is advised because the medicine's effects on alertness can vary among individuals.

Q: Can Cetallerg be used during the hay fever season for months at a time?

A: The medicine is indicated for relief of symptoms of seasonal allergic rhinitis, a condition that may require administration over an extended period. However, there are reports of severe itching if the medicine is stopped after prolonged use.

Q: What are the signs of a serious allergic reaction to Cetallerg?

A: Official warnings state that a severe allergic reaction to the product is possible. If an individual believes they are having a serious reaction, the product should be discontinued and medical help should be sought immediately.

Q: Does Cetallerg affect sleep patterns?

A: Yes, the medicine can affect sleep patterns. Drowsiness (somnolence) is a common side effect. Less commonly, official reports also list trouble sleeping (insomnia) as a possible undesirable effect.

Q: Can I stop taking Cetallerg suddenly without problems?

A: Official warnings indicate that cases of pruritus (severe itching) have been reported in some patients who stopped taking Cetallerg after using it for a long period. This effect has been reported following prolonged use.

Q: Is Cetallerg listed as a medicine that should be avoided by pregnant individuals?

A: Official documents state that caution should be exercised when prescribing the medicine to pregnant or lactating women. Individuals who are pregnant or breastfeeding are advised in the product label to consult a health professional before use.

Q: What if I take too much Cetallerg by accident?

A: If too much of the medicine is taken, the central nervous system is primarily affected. Symptoms can include confusion, dizziness, restlessness, and sedation. In the event of an accidental overdose, immediate contact with a Poison Control Center is strongly advised.

Q: Can Cetallerg cause stomach upset or nausea?

A: Yes, official safety information lists stomach pain, nausea, vomiting, or diarrhea as possible common side effects of the medicine.

Q: Do studies support the long-term use of Cetallerg for chronic hives?

A: Yes, Cetallerg is specifically indicated in regulatory documents for the relief of chronic idiopathic urticaria (hives). This is a condition that, by its chronic nature, requires ongoing treatment.

Q: Does Cetallerg have any known effect on liver function?

A: Instances of abnormal liver function have been reported. This includes elevated levels of liver enzymes and bilirubin. These effects are typically reported to be reversible and often resolve when the treatment is stopped.

Q: How should Cetallerg be stored?

A: Official instructions advise storing the medicine at room temperature, typically between 20^circ-25 C (68^circ-77 F). It should be protected from light, high humidity, and excessive heat above 40 C (104 F).

Q: Is Cetallerg known to cause dizziness?

A: Yes, dizziness is reported in official documents as one of the minor undesirable effects associated with the central nervous system at recommended doses.

How should Cetallerg be stored and disposed of?

The storage and disposal of Cetallerg must strictly adhere to the conditions mandated by official regulatory labeling to ensure product integrity.

Storage Classification	Requirement
Temperature Range	Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F).
Environmental Control	Protect the medication from heat and excessive moisture; the oral solution form also requires protection from light.
Packaging	Keep the product in the original container, which should remain tightly closed. Do not use the medication if the blister pack or safety seal is broken.
Child Safety	The medication must be kept out of the sight and reach of children at all times.

For disposal of unused or expired product, the official requirement is to use a drug take-back program. If a take-back program is unavailable, the medicine should be discarded in household trash after mixing it with an undesirable substance (e.g., used coffee grounds or dirt) and placing the mixture in a sealed container.

Cetallerg